BrUOG-Brain-223:A Study of PPX (CT-2103), Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors (CTI # CT2103)
| Status: | Archived |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | October 2008 |
| End Date: | December 2010 |
BrUOG-Brain-223-A Phase II Study of PPX (CT-2103), Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors (CTI # CT2103) Principal Investigator: Howard Safran, M.D.
The purpose of this study is to determine the antitumor activity of PPX in combination with
temozolomide and radiation for patients with newly diagnosed brain tumors.
To evaluate the safety/tolerability and potential antitumor activity of PPX in combination
with temozolomide and radiation for patients with newly diagnosed brain tumors.
We found this trial at
1
site
Click here to add this to my saved trials
